BACKGROUND & AIMS: Progression of liver fibrosis in experimental models depends on gut-derived bacterial products, but little is known about mechanisms of disruption of the mucosal barrier or translocation. We used a mouse model of cholestatic liver disease to investigate mechanisms of intestinal barrier disruption following liver injury. METHODS: Liver fibrosis and bacterial translocation were assessed in Toll-like receptor 2 (TLR2)-deficient and tumor necrosis factor receptor I (TNFRI)-deficient mice subjected to bile duct ligation. Epithelial and lamina propria cells were isolated and analyzed by immunoblot analyses and flow cytometry. We analyzed bone marrow chimeras and mice with a conditional gain-of-function allele for the TNFRI receptor. By crossing TNFRI(flxneo/flxneo) mice with mice that expressed the VillinCre transgene specifically in intestinal epithelial cells, we created mice that express functional TNFRI specifically on intestinal epithelial cells (VillinCreTNFRI(flxneo/flxneo) mice). RESULTS: Following bile duct ligation, TLR2-deficient mice had less liver fibrosis and intestinal translocation of bacteria and bacterial products than wild-type mice. Mice with hematopoietic cells that did not express TLR2 also had reduced bacterial translocation, indicating that TLR2 expression by hematopoietic cells regulates intestinal barrier function. The number of TLR2(+) monocytes that produce tumor necrosis factor α increased in the intestinal lamina propria of wild-type mice following bile duct ligation; bacterial translocation was facilitated by TNFRI-mediated signals on intestinal epithelial cells. CONCLUSIONS: Intestinal inflammation and bacterial translocation contribute to liver fibrosis via TLR2 signaling on monocytes in the lamina propria and TNFRI signaling on intestinal epithelial cells in mice. Therefore, enteric TNFRI is an important mediator of cholestatic liver fibrosis.
BACKGROUND & AIMS: Progression of liver fibrosis in experimental models depends on gut-derived bacterial products, but little is known about mechanisms of disruption of the mucosal barrier or translocation. We used a mouse model of cholestatic liver disease to investigate mechanisms of intestinal barrier disruption following liver injury. METHODS:Liver fibrosis and bacterial translocation were assessed in Toll-like receptor 2 (TLR2)-deficient and tumor necrosis factor receptor I (TNFRI)-deficient mice subjected to bile duct ligation. Epithelial and lamina propria cells were isolated and analyzed by immunoblot analyses and flow cytometry. We analyzed bone marrow chimeras and mice with a conditional gain-of-function allele for the TNFRI receptor. By crossing TNFRI(flxneo/flxneo) mice with mice that expressed the VillinCre transgene specifically in intestinal epithelial cells, we created mice that express functional TNFRI specifically on intestinal epithelial cells (VillinCreTNFRI(flxneo/flxneo) mice). RESULTS: Following bile duct ligation, TLR2-deficientmice had less liver fibrosis and intestinal translocation of bacteria and bacterial products than wild-type mice. Mice with hematopoietic cells that did not express TLR2 also had reduced bacterial translocation, indicating that TLR2 expression by hematopoietic cells regulates intestinal barrier function. The number of TLR2(+) monocytes that produce tumor necrosis factor α increased in the intestinal lamina propria of wild-type mice following bile duct ligation; bacterial translocation was facilitated by TNFRI-mediated signals on intestinal epithelial cells. CONCLUSIONS:Intestinal inflammation and bacterial translocation contribute to liver fibrosis via TLR2 signaling on monocytes in the lamina propria and TNFRI signaling on intestinal epithelial cells in mice. Therefore, enteric TNFRI is an important mediator of cholestatic liver fibrosis.
Authors: Le Shen; Eric D Black; Edwina D Witkowski; Wayne I Lencer; Vince Guerriero; Eveline E Schneeberger; Jerrold R Turner Journal: J Cell Sci Date: 2006-04-25 Impact factor: 5.285
Authors: Fuyumi Isayama; Ian N Hines; Michael Kremer; Richard J Milton; Christy L Byrd; Ashley W Perry; Stephen E McKim; Christopher Parsons; Richard A Rippe; Michael D Wheeler Journal: Am J Physiol Gastrointest Liver Physiol Date: 2006-01-26 Impact factor: 4.052
Authors: Daniel R Clayburgh; Terrence A Barrett; Yueming Tang; Jon B Meddings; Linda J Van Eldik; D Martin Watterson; Lane L Clarke; Randall J Mrsny; Jerrold R Turner Journal: J Clin Invest Date: 2005-09-22 Impact factor: 14.808
Authors: Rubén Francés; Maite Chiva; Elisabet Sánchez; José M González-Navajas; Teresa Llovet; Pedro Zapater; Germán Soriano; Carlos Muñoz; Joaquín Balanzó; Miguel Pérez-Mateo; Xiao-yu Song; Carlos Guarner; José Such Journal: J Hepatol Date: 2006-12-27 Impact factor: 25.083
Authors: Georgios I Tsiaoussis; Stelios F Assimakopoulos; Athanassios C Tsamandas; Christos K Triantos; Konstantinos C Thomopoulos Journal: World J Hepatol Date: 2015-08-18
Authors: Magdalena Mazagova; Lirui Wang; Andrew T Anfora; Max Wissmueller; Scott A Lesley; Yukiko Miyamoto; Lars Eckmann; Suraj Dhungana; Wimal Pathmasiri; Susan Sumner; Caroline Westwater; David A Brenner; Bernd Schnabl Journal: FASEB J Date: 2014-12-02 Impact factor: 5.191
Authors: Lirui Wang; Phillipp Hartmann; Michael Haimerl; Sai P Bathena; Christopher Sjöwall; Sven Almer; Yazen Alnouti; Alan F Hofmann; Bernd Schnabl Journal: J Hepatol Date: 2014-02-19 Impact factor: 25.083